Turkish Minister of Health: China’s Kexing vaccine is safe and effective, initially showing an effective rate of 91.25% | Brazil_Sina Finance_Sina.com

Original title: Turkish Minister of Health: China’s Kexing vaccine is safe and effective, initially showing an effective rate of 91.25%

[Texto / Red de observadores Liu Chenghui]Following the statement by the Brazilian Institute Butantan that the new corona vaccine “CoronaVac” (CoronaVac) controlled by China Kexing is safe and effective, Turkish Health Minister Fahrettin Koca said on the 24th that preliminary data show the effectiveness of Kexing vaccine up to 91.25%. Koja also announced that he would work with medical staff to become the first group to receive the vaccine.

According to reports from Reuters and Turkey’s Anadolu Agency, after attending Turkey’s New Coronavirus Scientific Advisory Committee meeting on the 24th, Koca announced at the press conference that in the country’s Phase III clinical trials, the data preliminary showed The effectiveness of the Chinese vaccine is 91.25%. The first batch of 3 million doses of vaccine will arrive in Turkey on the 28th.

According to Reuters, the trial in Turkey began on September 14 this year and more than 7,000 volunteers participated. The Turkish researchers said that the results of this test are based on test data from 1,322 people.

The researchers revealed that in the late stage of the “Kellyford” vaccine trial, except for an allergic reaction in one patient, no other serious adverse reactions occurred during the trial.

Koca presented at the press conference that of the 29 people who were diagnosed with infection during the trial, 26 were in the control group. Follow-up trials will continue until 40 people are infected. Koja revealed that the Turkish researchers had planned to announce the results after 40 people were infected, but the data showed that the vaccine was safe and the side effects of these volunteers after the vaccine were very small.

“Despite the risks, we are very optimistic about the situation. The three people who tested positive did not have fever or respiratory problems,” Koja said.Now we confirm that the Chinese vaccine is safe and effective for the Turks. ” These test data will serve as the basis for the Turkish government to approve the Kexing vaccine.

Turkey has signed an agreement to buy up to 50 million doses of the Coxing vaccine. The original plan was to arrive on December 11, but the delivery was delayed. Koja said that although the licensing issue has affected delivery time, the first batch of 3 million doses of vaccines will be shipped on the 27th and will arrive in Turkey the next day. The government will prioritize vaccinating 9 million people. , including medical personnel.

In addition to the Kexing vaccine, Turkey will also sign an agreement to purchase the new crown vaccine from Pfizer / BioNTech, obtaining 4.5 million doses by the end of March next year, and has the option to purchase an additional 30 million doses.

According to statistics from Johns Hopkins University in the United States, at 7:22 am on the 25th Beijing time, the cumulative number of confirmed cases in Turkey reached 2,100,712 and the cumulative number of deaths was 19,115. On the 24th, Turkey added 18,102 confirmed cases and 254 deaths.

It is worth mentioning that Brazil also completed the third phase of the “Kellyford” vaccine shortly before the release of the test data in Turkey. According to the sources involved in the trial, the results of the trial showed that the effectiveness of Kexing’s new corona vaccine “Kierlaifu” exceeded 50%, which exceeded the 50% effectiveness threshold recognized by international scientists. This means that Brazilian regulators can give the green light to the use of the vaccine, and this vaccine is expected to become the first batch of new corona vaccines approved for use in Brazil.

However, the Brazilian Butantan Institute, which conducted the test, confirmed that Kexing Company still needs to delay 15 days to publish the results because they need to integrate the test data from Turkey and Indonesia.

As the new corona epidemic is basically under control in China, Chinese vaccine developers have to conduct clinical trials abroad. Currently, the “Kierlaifu” vaccine has undergone clinical trials in Brazil, Turkey, and Indonesia, and only Brazil has completed phase III clinical trials of the vaccine.

The “Wall Street Journal” once noted that, compared to the Pfizer vaccine, “Claireford” has obvious advantages in terms of transportation conditions. Pfizer vaccine can only be stored in an environment of minus 70 degrees Celsius, while “Kierlai Fu” can be stored at a normal refrigerator temperature of 2 to 8 degrees Celsius. This kind of nature that can be stored in common refrigerators has made many underdeveloped regions pin their hopes on Chinese vaccines.

Editor in charge: Li Ang